New arm therapy could help stroke survivors reach further

NCT ID NCT04118998

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This study tests a new exercise therapy called Progressive Abduction Loading Therapy for people who recently had a stroke. The goal is to reduce a common arm problem called 'flexion synergy' that makes it hard to reach outward. 86 participants will receive either the new therapy or standard supported reaching exercises, and be tracked for one year to see if arm function improves.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Progressive Abduction Loading Therapy (a behavioral exercise therapy)
What this could lead to
If it works, this could lead to a better rehabilitation method that helps stroke survivors regain arm movement and reduce long-term disability.
What could go wrong
This is a mid-stage trial with only 86 participants, so results may not apply to all stroke survivors. The therapy is behavioral, so benefits may be modest and depend on individual effort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE/SUBACUTE ISCHEMIC STROKE IN THE MIDDLE CEREBRAL ARTERY DISTRIBUTION WITH HEMIPARESIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Physical Therapy and Human Movement Sciences

    Chicago, Illinois, 60611, United States

  • Northwestern Medicine Marianjoy Rehabilitation Hospital

    Wheaton, Illinois, 60187, United States

  • Shirley Ryan AbilityLab

    Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.